-- Days : -- HRS : -- MIN : -- SEC
Register Now →

All News

Patients with iCCA, particularly those whose disease progresses following first-line chemotherapy, have limited overall treatment options. Data presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting show that patients may soon have a new agent to fight this rare cancer in futibatinib (Taiho Oncology), an FGFR inhibitor.

Image of a red AIDS ribbon

A possible connection between integrase strand-transfer inhibitor (INSTI) use for HIV and cardiovascular disease (CVD) was investigated in this new study from an international team wanting more knowledge on the drug class’s treatment effects.